Every article, report, and earnings note where CORT appears.
Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.
Corcept Therapeutics Incorporated (CORT) jumps after hours as investors react to its Q2 2026 earnings event and a fresh price-target hike from Canaccord Genuity. The stock moved sharply above its prior 52-week high, but valuation remains stretched and analyst views are sharply divided.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate CORT ReportCancel anytime